NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Featured in ROTH Equity Research Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Yesterday, CLRB reported clinical results from two hematological malignancy trials, notably demonstrating robust ORR (100% ORR in LPL/WM; 43% ORR in MM at highest dose) and a 100% DCR in all patients After further data analyses over 2020, CLRB will pick a lead indication (MM or LPL/WM), and likely begin a pivotal trial in 4Q20. We view the unfavorable share price response as totally unwarranted, especially given the differentiated potency and safety shown. We reiterate our Buy and…







